Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bmab3000 vs Herceptin Hylecta in Healthy Male Volunteers
NCT07299955Phase 1Completed
- Sponsor
- Mylan
- Start
- Feb 2026
- Primary completion
- Sep 2026
- Modality
- Therapeutic Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Bmab3000 in breast cancer (2 arms), sponsored by Mylan. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve from Time Zero to Infinity. Started Feb 2026; status: completed.
02
Drugs
Bmab3000
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07299955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299955.